W. Brugger

572 total citations
18 papers, 463 citations indexed

About

W. Brugger is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, W. Brugger has authored 18 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Hematology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in W. Brugger's work include Hematopoietic Stem Cell Transplantation (6 papers), Neutropenia and Cancer Infections (4 papers) and Cancer Treatment and Pharmacology (3 papers). W. Brugger is often cited by papers focused on Hematopoietic Stem Cell Transplantation (6 papers), Neutropenia and Cancer Infections (4 papers) and Cancer Treatment and Pharmacology (3 papers). W. Brugger collaborates with scholars based in Germany, Austria and Switzerland. W. Brugger's co-authors include Lothar Kanz, R Mertelsmann, RJ Berenson, S Heimfeld, R Mertelsmann, Stefan Scheding, Karsten Kratz‐Albers, Federico Cappuzzo, Bernhard Meister and Renaud Whittom and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

W. Brugger

16 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Brugger Germany 9 248 207 127 101 93 18 463
Peggy Russell United States 7 372 1.5× 141 0.7× 124 1.0× 100 1.0× 81 0.9× 9 526
J.-O. Bay France 10 122 0.5× 138 0.7× 84 0.7× 78 0.8× 82 0.9× 24 370
M Teramura Japan 9 288 1.2× 116 0.6× 163 1.3× 167 1.7× 48 0.5× 11 516
LR Ellingsworth United States 5 240 1.0× 95 0.5× 101 0.8× 224 2.2× 39 0.4× 8 429
M. H. Purdy United States 4 246 1.0× 224 1.1× 59 0.5× 74 0.7× 48 0.5× 7 439
M. M. Uttenreuther-Fischer Germany 13 101 0.4× 198 1.0× 143 1.1× 201 2.0× 57 0.6× 24 542
N Belli Italy 7 461 1.9× 248 1.2× 106 0.8× 100 1.0× 25 0.3× 11 568
Bühring Hj Germany 7 281 1.1× 138 0.7× 158 1.2× 211 2.1× 23 0.2× 12 538
Curtis Je Canada 9 220 0.9× 88 0.4× 78 0.6× 167 1.7× 35 0.4× 12 388
NS Wolf United States 9 483 1.9× 123 0.6× 165 1.3× 274 2.7× 87 0.9× 13 741

Countries citing papers authored by W. Brugger

Since Specialization
Citations

This map shows the geographic impact of W. Brugger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Brugger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Brugger more than expected).

Fields of papers citing papers by W. Brugger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Brugger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Brugger. The network helps show where W. Brugger may publish in the future.

Co-authorship network of co-authors of W. Brugger

This figure shows the co-authorship network connecting the top 25 collaborators of W. Brugger. A scholar is included among the top collaborators of W. Brugger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Brugger. W. Brugger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Brugger, W., Nadja Triller, Maria Błasińska-Morawiec, et al.. (2009). Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. Journal of Clinical Oncology. 27(15_suppl). 8020–8020. 49 indexed citations
2.
Brugger, W., et al.. (2009). 9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC. European Journal of Cancer Supplements. 7(2). 559–559. 13 indexed citations
3.
Soulières, Denis, T-E. Ciuleanu, Renaud Whittom, et al.. (2009). 9167 Outcomes with erlotinib in advanced NSCLC: examining the influence of increased EGFR gene copy number and EGFR mutations. European Journal of Cancer Supplements. 7(2). 556–556. 2 indexed citations
4.
Freier, Werner, Hans‐Joachim Stemmler, G. Gitsch, et al.. (2008). Randomised trial comparing gemcitabine plus vinorelbine (Gem/Vin), gemcitabine plus cisplatin (Gem/Cis), and gemcitabine plus capecitabine (Gem/Cap) in pretreated metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1054–1054. 2 indexed citations
5.
6.
Scheding, Stefan, Karsten Kratz‐Albers, Bernhard Meister, W. Brugger, & Lothar Kanz. (1998). Ex vivo expansion of hematopoietic progenitor cells for clinical use.. PubMed. 35(3). 232–40. 28 indexed citations
7.
8.
Brugger, W., R. Engelhardt, R Mertelsmann, & Lothar Kanz. (1994). The management of primary mediastinal B-cell lymphoma with sclerosis. Annals of Oncology. 5(10). 943–947. 4 indexed citations
9.
Henschler, Reinhard, W. Brugger, Lothar Kanz, & R Mertelsmann. (1994). Haematopoietic growth factors in clinical medicine. European Journal of Cancer. 30(1). 118–119. 3 indexed citations
10.
Brugger, W., Roland Mertelsmann, & Lothar Kanz. (1994). Mobilization, purification and ex vivo expansion of human peripheral blood progenitor cells. PubMed. 35(3). 24–28. 2 indexed citations
11.
Halle, Martin, Ulrike Blum, Ernst Dinkel, & W. Brugger. (1993). CT and MR Features of Primary Pulmonary Hemangiopericytomas. Journal of Computer Assisted Tomography. 17(1). 51–55. 16 indexed citations
12.
13.
14.
Drings, P., I Günther, U. Gatzemeier, et al.. (1992). Final Evaluation of a Phase II Study on the Effect of Edelfosine (an Ether Lipid) in Advanced Non-Small-Cell Bronchogenic Carcinoma. Oncology Research and Treatment. 15(5). 375–382. 17 indexed citations
15.
Herrmann, F., W. Brugger, Lothar Kanz, & R Mertelsmann. (1992). In vivo biology and therapeutic potential of hematopoietic growth factors and circulating progenitor cells.. PubMed. 19(4). 422–31. 19 indexed citations
16.
Brugger, W., et al.. (1992). Role of hematopoietic growth factor combinations in experimental and clinical oncology.. PubMed. 19(2 Suppl 4). 8–15. 5 indexed citations
17.
18.
Fölsch, E, et al.. (1975). [Modification of hematotoxic effects of cyclophosphamide by anabolid steroids].. PubMed. 25(1). 59–66.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peggy Russell Breakdown of academic impact, for papers by J.-O. Bay Breakdown of academic impact, for papers by M Teramura Breakdown of academic impact, for papers by LR Ellingsworth Breakdown of academic impact, for papers by M. H. Purdy Breakdown of academic impact, for papers by M. M. Uttenreuther-Fischer Breakdown of academic impact, for papers by N Belli Breakdown of academic impact, for papers by Bühring Hj Breakdown of academic impact, for papers by Curtis Je Breakdown of academic impact, for papers by NS Wolf
Rankless by CCL
2026